SEC Comment Letter 0000000000-23-004992 to Neuphoria Therapeutics Inc. (NEUP) (CIK 0001191070) (NEUP)
Neuphoria Therapeutics Inc. (NEUP) (CIK 0001191070)
Date: May 11, 2023 · CIK: 0001191070 · Accession: 0000000000-23-004992
AI Filing Summary & Sentiment
File numbers found in text: 333-271696
Letter
United States securities and exchange commission logo May 11, 2023 Spyridon Papapetropoulos Chief Executive Officer Bionomics Limited 2710 Gateway Oaks Drive, Suite 150N Sacramento, CA 95833 Re:Bionomics Limited Registration Statement on Form F-3 Filed May 5, 2023 File No. 333-271696 Dear Spyridon Papapetropoulos: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Michael E. Sullivan, Esq.
Show Raw Text
United States securities and exchange commission logo
May 11, 2023
Spyridon Papapetropoulos
Chief Executive Officer
Bionomics Limited
2710 Gateway Oaks Drive, Suite 150N
Sacramento, CA 95833
Re:Bionomics Limited
Registration Statement on Form F-3
Filed May 5, 2023
File No. 333-271696
Dear Spyridon Papapetropoulos:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Michael E. Sullivan, Esq.